. 2010 Dec 14;16(46):5889–5894. doi: 10.3748/wjg.v16.i46.5889

Table 1.

Trials comparing irinotecan-containing and nonirinotecan-containing combination chemotherapies, treatment schedule and quality of each trial

Study	Regimen	Patients (n)	RR (%)	Survival (mo)
Study	Regimen	Patients (n)	RR (%)	Progression free	Overall
Bouché et al[18]	FU	45	13.0	3.2	6.8
	CF	44	27.0	4.9	9.5
	IF	45	40.0	6.9	11.3
Moehler et al[19]	ILF	56	42.9	4.5	10.8
Moehler et al[19]	ELF	58	24.1	2.3	8.3
Dank et al[20]	IF	170	31.8		9.0
Dank et al[20]	CF	163	25.8		8.7
Nakashima et al[21]	IP	44	47.0	5.7	14.8
Nakashima et al[21]	SP	32	80.0	7.8	15.6

FU: Fluorouracil; CF: Cisplatin and FU; IF: Irinotecan and FU; RR: Response rate; ILF: Irinotecan, leucovorin and FU; ELF: Etoposide, leucovorin and FU; IP: Irinotecan and cisplatin; SP: S-1 and cisplatin.